The recent publication by Amisaki et al.1 in Nature highlights a novel and druggable mechanism by which IL-33-activated innate lymphoid cells type 2 (ILC2s) induce the formation of tertiary lymphoid structures (TLSs) within the tumor microenvironment (TME) of pancreatic cancer. This evidence concerns the gene IL33 and neoplasm.